Biogen Inc. Share Price

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 17/05/2024 BST 5-day change 1st Jan Change
230.6 USD +0.23% Intraday chart for Biogen Inc. +4.09% -10.90%
Sales 2024 * 9.52B 750B Sales 2025 * 9.55B 752B Capitalization 33.57B 2,643B
Net income 2024 * 1.9B 149B Net income 2025 * 2.21B 174B EV / Sales 2024 * 3.84 x
Net Debt 2024 * 3.01B 237B Net Debt 2025 * 536M 42.19B EV / Sales 2025 * 3.57 x
P/E ratio 2024 *
17.8 x
P/E ratio 2025 *
15.4 x
Employees 7,570
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.23%
1 week+4.09%
Current month+7.33%
1 month+21.02%
3 months+5.24%
6 months+1.13%
Current year-10.90%
More quotes
1 week
221.72
Extreme 221.72
236.90
1 month
192.75
Extreme 192.75
236.90
Current year
189.44
Extreme 189.44
268.30
1 year
189.44
Extreme 189.44
319.76
3 years
187.16
Extreme 187.16
468.55
5 years
187.16
Extreme 187.16
468.55
10 years
187.16
Extreme 187.16
480.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 13/11/22
Director of Finance/CFO 60 14/08/20
Chief Operating Officer - 31/12/14
Members of the board TitleAgeSince
Director/Board Member 75 31/12/09
Director/Board Member 70 18/06/19
Chairman 64 02/01/10
More insiders
Date Price Change Volume
17/05/24 230.6 +0.23% 985,059
16/05/24 230 -2.24% 936,678
15/05/24 235.3 +3.72% 1,792,660
14/05/24 226.9 +0.68% 1,126,999
13/05/24 225.3 +1.73% 1,274,672

Delayed Quote Nasdaq, May 17, 2024 at 09:00 pm

More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230.6 USD
Average target price
285.9 USD
Spread / Average Target
+24.01%
Consensus